Literature DB >> 3527727

Human hepatocyte growth factor in plasma from patients with fulminant hepatic failure.

E Gohda, H Tsubouchi, H Nakayama, S Hirono, K Takahashi, M Koura, S Hashimoto, Y Daikuhara.   

Abstract

Plasma from patients with fulminant hepatic failure obtained during plasma exchange therapy, like their serum, demonstrated marked stimulatory activity on DNA synthesis in cultured rat hepatocytes. Heat treatment at 56 degrees C for 30 min did not affect this activity of the plasma, but reduced that of the serum. This growth-promoting activity was confirmed by showing that the patients' serum and plasma increased the labeling index with [3H]thymidine and the total number of nuclei in hepatocyte cultures. The activity of pooled active fractions obtained by gel filtration of the heated plasma was lost completely on heat treatment at 80 degrees C for 10 min or on treatment with trypsin or chymotrypsin, which suggests that it was due to a protein. The human hepatocyte growth factor was purified about 600-fold from heated plasma of a patient by ammonium sulfate precipitation and chromatographies on Affi-Gel Blue and hydroxylapatite. The maximum effect of this partially purified factor on DNA synthesis in cultured hepatocytes was greater than that of epidermal growth factor. The molecular weight of the hepatocyte growth factor was about 85,000 as determined by SDS-PAGE.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3527727     DOI: 10.1016/0014-4827(86)90514-8

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  28 in total

1.  Mechanisms controlling growth of hepatocytes in primary culture.

Authors:  A Ichihara
Journal:  Dig Dis Sci       Date:  1991-04       Impact factor: 3.199

2.  Inhibitors of hepatic DNA synthesis in fulminant hepatic failure.

Authors:  R D Hughes; H Yamada; C D Gove; R Williams
Journal:  Dig Dis Sci       Date:  1991-06       Impact factor: 3.199

Review 3.  Liver regeneration in relationship to acute liver failure.

Authors:  C D Gove; R D Hughes
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

4.  The MET axis as a therapeutic target.

Authors:  Martin Sattler; Ravi Salgia
Journal:  Update Cancer Ther       Date:  2009-04-01

5.  Apoptosis of serum-free C2.8 mouse embryo hepatocytic cells caused by hepatocyte growth factor deprivation.

Authors:  R P Revoltella; F Borney; B Dal Canto; C M D'Urso
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

6.  Administration of hepatic stimulatory substance alone or with other liver growth factors does not ameliorate acetaminophen-induced liver failure.

Authors:  A Francavilla; A Azzarone; G Carrieri; U Cillo; D Van Thiel; V Subbottin; T E Starzl
Journal:  Hepatology       Date:  1993-03       Impact factor: 17.425

7.  Inhibition of the ubiquitin ligase activity improves the production of biologically active fusion protein HSA-HGF in Chinese hamster ovary cells.

Authors:  Dongsheng Xu; Aini Wan; Jingjing Zhang; Lin Peng; Yun Chen; Yang He; Jianfeng Yang; Jian Jin
Journal:  Bioengineered       Date:  2016-10-18       Impact factor: 3.269

Review 8.  c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy.

Authors:  Martin Sattler; Ravi Salgia
Journal:  Curr Oncol Rep       Date:  2007-03       Impact factor: 5.075

9.  Purification and partial characterization of hepatocyte growth factor from plasma of a patient with fulminant hepatic failure.

Authors:  E Gohda; H Tsubouchi; H Nakayama; S Hirono; O Sakiyama; K Takahashi; H Miyazaki; S Hashimoto; Y Daikuhara
Journal:  J Clin Invest       Date:  1988-02       Impact factor: 14.808

10.  Circulating proinflammatory cytokines (IL-1 beta, TNF-alpha, and IL-6) and IL-1 receptor antagonist (IL-1Ra) in fulminant hepatic failure and acute hepatitis.

Authors:  K D Sekiyama; M Yoshiba; A W Thomson
Journal:  Clin Exp Immunol       Date:  1994-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.